ArticleACS omega2026
Thermally Activated Vaporization of Fluorocarbon-In-Hydrocarbon Exoskeletal Droplets.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prior research has demonstrated synthesis and vaporization of hydrocarbon (HC)-in-fluorocarbon (H/F/W) endoskeletal droplets in aqueous suspension through the use of a fluorosurfactant and their potential utility as photoacoustic contrast agents. Here, we describe the synthesis of novel fluorocarbon-in-hydrocarbon (F/H/W) exoskeletal droplets through the choice of phospholipid surfactant. Exoskeletal drops tended to form nonspherical structures due to the elasticity of the solid HC shell. Vaporization of exoskeletal droplets occurred over a longer time scale than endoskeletal droplets due to constricted vapor nucleation and growth, and the resulting bubbles were significantly smaller. The size distribution of the exoskeletal droplets and the resulting bubbles could be further reduced through filtration. In contrast to endoskeletal droplets, which rapidly vaporized from a single nucleation site, exoskeletal droplets formed multiple nucleation sites during vaporization. Heat treatment with quenching increased the number of nucleation sites on each vaporizing droplet. The improved biocompatibility and ability to control the process of vaporization for exoskeletal droplets may be advantageous for medical imaging and other applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.